T&M - Tysabri® intravenous (IV) versus Tysabri subcutaneous (SC)
Research type
Research Study
Full title
Time and Motion (T&M) study to quantify the preparation and administration burden of Tysabri® intravenous (IV) versus Tysabri subcutaneous (SC) for the treatment of multiple sclerosis (MS) (TiMoTys)
IRAS ID
318021
Contact name
Tarunya Arun
Contact email
Sponsor organisation
Biogen
Duration of Study in the UK
0 years, 5 months, 0 days
Research summary
The main purpose of this study is to compare the Tysabri Intravenous (IV) and Sub-Cutaneous (SC) workflows (including preparation, administration, and post-treatment observation) and to quantify active Health Care Professionals time and total patient time associated with Tysabri IV and SC workflows.
HCPs are considered as participants within this study. Patients are not considered as partipants to the study, they will receive normal standard of care throughout and will be advised whilst receiving treatment that the study is ongoing.
REC name
London - Brent Research Ethics Committee
REC reference
23/PR/0266
Date of REC Opinion
13 Mar 2023
REC opinion
Favourable Opinion